Keyphrases
Molecular Targets
100%
Endometrial Cancer
100%
Cancer Treatment
100%
Recurrence Prediction
100%
Deubiquitinating Enzyme
100%
USP14
100%
Chemoresistance
50%
Endometrial Cancer Cells
50%
Cell Growth
25%
Cell Viability
25%
United States
25%
Cancer Patients
25%
Targeted Therapy
25%
Human Cancer
25%
Small Molecule Inhibitors
25%
Recurrence Risk
25%
Cancer Progression
25%
Cell Differentiation
25%
In Situ
25%
Apoptosis
25%
Chemotherapy Resistance
25%
Cancer Initiation
25%
Endometrial Adenocarcinoma
25%
Protein Degradation Pathways
25%
FDA-approved Drugs
25%
High Mortality
25%
Cancer Cases
25%
Growth Differentiation
25%
Master Regulator
25%
Caspase-3
25%
Cell Apoptosis
25%
Cell Cycle Arrest
25%
Metabolic Processes
25%
Ki-67
25%
Proliferation Marker
25%
Selective Inhibition
25%
Good Prognosis
25%
Disease Experience
25%
Pharmacological Targeting
25%
Cancer Onset
25%
VLX1570
25%
Promising Biomarkers
25%
Working Diagnosis
25%
Gynecologic Malignancies
25%
Ubiquitin-mediated Protein Degradation
25%
Medicine and Dentistry
Cancer Therapy
100%
Recurrent Disease
100%
Uterine Cancer
100%
Deubiquitinase
66%
Cancer Cell
33%
Programmed Cell Death
33%
Drug Resistance
33%
Malignant Neoplasm
16%
Cell Growth
16%
Disease
16%
Biological Marker
16%
Chemotherapy
16%
Cancer
16%
Targeted Therapy
16%
Cancer Growth
16%
Endometrium Carcinoma
16%
Cell Cycle Arrest
16%
Cell Viability
16%
Protein Degradation
16%
Cell Cycle Checkpoint
16%
Caspase 3
16%
Ubiquitin
16%
Pharmacology, Toxicology and Pharmaceutical Science
Molecular Target
100%
Endometrium Cancer
100%
Recurrent Disease
100%
Deubiquitinase
66%
Malignant Neoplasm
33%
Drug Resistance
33%
Chemotherapy
16%
Cell Viability
16%
Biological Marker
16%
Cancer Growth
16%
Endometrium Carcinoma
16%
Disease
16%
Caspase 3
16%
Ubiquitin
16%
Biochemistry, Genetics and Molecular Biology
Deubiquitinating Enzyme
100%
USP14
100%
Cancer Cell
50%
Drug Resistance
50%
Small Molecule
25%
Protein Catabolism
25%
Cell Viability
25%
Cell Cycle Arrest
25%
Cell Cycle Checkpoint
25%
Caspase 3
25%
Ubiquitin
25%
Cell Growth
25%